L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction

Ann Thorac Surg. 1997 Aug;64(2):414-20. doi: 10.1016/s0003-4975(97)00476-1.

Abstract

Background: Cyclosporin A is known to alter endothelium-dependent responses to different agonists. Few data are available concerning the effect of cyclosporin A on the pulmonary vascular bed.

Methods: The endothelium-dependent responses to acetylcholine (20 micrograms), bradykinin (5 micrograms), and substance P (5 micrograms) were investigated in a dog model of left lung autoperfusion at constant flow.

Results: The vasodilator response to bradykinin and substance P was significantly decreased with cyclosporin A (20 mg) administration. The average decreases in pulmonary arterial pressure with bradykinin were 5.4 +/- 1.5 mm Hg and 2.4 +/- 0.4 mm Hg before and after cyclosporin A administration, respectively (p = 0.04). The average decreases in pulmonary arterial pressure with substance P were 4.4 +/- 1.0 mm Hg and 1.8 +/- 0.5 mm Hg before and after cyclosporin A administration, respectively (p = 0.04). The responses to acetylcholine and the endothelium-independent relaxing agent nitroglycerin were not significantly affected by cyclosporin A. The effects of cyclosporin A on endothelium-dependent responses to bradykinin and substance P were overcome by the administration of L-arginine (200 mg/kg intravenously). The decreased response to bradykinin and substance P after cyclosporin A administration was not significantly affected by indomethacin, a cyclooxygenase inhibitor. The pulmonary angiotensin-converting enzyme activity was also measured using [3H]benzoyl-phenylalanyl-glycyl-proline, an inactive angiotensin-converting enzyme substrate. There was an average [3H]benzoyl-phenylalanyl-glycyl-proline hydrolysis of 54% +/- 2% and 55% +/- 2% before and after cyclosporin A administration, respectively (not significant).

Conclusions: The present study suggests that cyclosporin A selectively decreases endothelium-dependent responses to bradykinin and substance P without affecting the cyclic guanosine monophosphate-dependent pathway in the canine pulmonary vascular bed. The decreased endothelium-dependent responses to bradykinin and substance P are not related to increased angiotensin-converting enzyme activity. The toxic effect of cyclosporin A on endothelium-dependent responses is reversible by the administration of L-arginine, a source of substrate for nitric oxide.

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Arginine / pharmacology*
  • Atrial Function, Left / drug effects
  • Blood Pressure / drug effects
  • Bradykinin / pharmacology
  • Cyclooxygenase Inhibitors / pharmacology
  • Cyclosporine / toxicity*
  • Dogs
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Indomethacin / pharmacology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitroglycerin / pharmacology
  • Peptidyl-Dipeptidase A / metabolism
  • Pulmonary Artery
  • Pulmonary Circulation / drug effects*
  • Pulmonary Circulation / physiology
  • Substance P / pharmacology
  • Vasodilation / drug effects
  • Vasodilator Agents / pharmacology

Substances

  • Cyclooxygenase Inhibitors
  • Vasodilator Agents
  • Substance P
  • Cyclosporine
  • Arginine
  • Nitric Oxide Synthase
  • Peptidyl-Dipeptidase A
  • Nitroglycerin
  • Acetylcholine
  • Bradykinin
  • NG-Nitroarginine Methyl Ester
  • Indomethacin